For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

"While tirzepatide causes considerable weight loss, research is lacking on its effects on cardiovascular outcomes," lead study author Milton Packer, MD, distinguished scholar in cardiovascular science ...

New medication that can cut body weight by 23% could radically reduce the number of people who are obese. Tirzepatide is ...

In the efficacy estimand, tirzepatide compared with placebo demonstrated a significant increase in change in 6-minute walk distance (38.2 vs 7.9 meters), a greater change in body weight (-15.7 vs -2.2 ...

Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Hundreds of people are dead and thousands infected in Sudan's months-long cholera outbreak. A recent statistic from the ...